Rapid repigmentation after depigmentation therapy: Vitiligo treated with monobenzyl ether of hydroquinone

Australasian Journal of Dermatology

Volumn 37, Issue 2, 1996, Pages 96-98

  Oakley, Amanda M M ^a,b  

^a WAIKATO HOSPITAL   (New Zealand)

^b Tristram Plast Surg and Dermatol   (New Zealand)

Author keywords

Leucoderma

Indexed keywords

HYDROQUINONE DERIVATIVE; MONOBENZONE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; HUMAN; MALE; PUVA; RECURRENT DISEASE; SKIN DISEASE; SKIN PIGMENTATION; VITILIGO;

ADULT; FACIAL DERMATOSES; HUMANS; HYDROQUINONES; MALE; PUVA THERAPY; RECURRENCE; SKIN PIGMENTATION; VITILIGO;

EID: 0030147477     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.1996.tb01014.x     Document Type: Article

References (4)

1. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzyl ether of hydroquinone: A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br. J. Dermatol. 1977; 97: 669-79.
2. Fisher AA, Differential diagnosis of idiopathic vitiligo. Part III: occupational leukoderma. Cutis 1994; 55: 232-4.
3. ICN Pharmaceuticals, Inc., Product data: Benoquin® Cream. ICN Pharmaceuticals Inc., Costa Mesa, CA, USA.
4. Spencer MC. Topical use of hydroquinone for depigmentation. JAMA 1965; 194: 114-16.